Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 12/20 | 0.48 |
| ▸ | XIAP | P98170 | 12/20 | 0.47 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357580 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL21106900 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL21471951 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL28788354 | 1.00 | BIRC2 (0.48) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL29312021 | 0.93 | BIRC2 (0.46) | BIRC2XIAPBIRC3RIPK2 | |
| SCHEMBL23572024 | 0.92 | TRPV1 (0.42) | BIRC2XIAPBIRC3 | |
| Lcl-161 SCHEMBL21064744 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 | |
| Lcl-161 SCHEMBL1275554 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 | |
| Lcl-161 SCHEMBL19164873 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 | |
| Lcl-161 SCHEMBL3688581 | 0.92 | XIAP (0.50) | BIRC2XIAPBIRC3RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | BIRC2 112/4885XIAP 7/4885BIRC3 239/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | BIRC2 112/4885XIAP 7/4885BIRC3 239/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | BIRC2 112/4885XIAP 7/4885BIRC3 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.